{"name":"Corcept Therapeutics","slug":"corcept","ticker":"CORT","exchange":"NASDAQ","domain":"corcept.com","description":"Corcept Therapeutics Inc. is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. Corcept has focused on the adverse effects of excess cortisol, studying new compounds that may mitigate those effects. Its executive team is headed by CEO, president and director Joseph K. Belanoff, MD.","hq":"Menlo Park, CA","founded":0,"employees":"730","ceo":"Joseph K. Belanoff","sector":"Endocrinology / Specialty Pharma","stockPrice":42.99,"stockChange":1.3,"stockChangePercent":3.12,"marketCap":"$4.6B","metrics":{"revenue":761407000,"revenueGrowth":11.1,"grossMargin":98.3,"rdSpend":254908000,"netIncome":99652000,"cash":372152000,"dividendYield":0,"peRatio":52.4,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Korlym patent cliff ($123.8M at risk)","drug":"Korlym","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"CORT118335 Oral","genericName":"CORT118335 Oral","slug":"cort118335-oral","indication":"Other","status":"phase_1"},{"name":"CORT125281, 120mg, fasted","genericName":"CORT125281, 120mg, fasted","slug":"cort125281-120mg-fasted","indication":"Other","status":"phase_1"},{"name":"Miricorilant 100 mg","genericName":"Miricorilant 100 mg","slug":"miricorilant-100-mg","indication":"Other","status":"phase_1"},{"name":"Miricorlilant","genericName":"Miricorlilant","slug":"miricorlilant","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"CORT118335 Oral","genericName":"CORT118335 Oral","slug":"cort118335-oral","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"CORT125281, 120mg, fasted","genericName":"CORT125281, 120mg, fasted","slug":"cort125281-120mg-fasted","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Miricorilant 100 mg","genericName":"Miricorilant 100 mg","slug":"miricorilant-100-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Miricorlilant","genericName":"Miricorlilant","slug":"miricorlilant","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Corcept Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Corcept Therapeutics reported its financial results for the fourth quarter and full year 2023, with net sales of $123.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Corcept Therapeutics Announces $100 Million Stock Repurchase Program","summary":"Corcept Therapeutics announced a $100 million stock repurchase program to enhance shareholder value.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"Corcept Therapeutics Announces Positive Topline Results from Phase 3 Clinical Trial of Korlym in Patients with Cushing's Syndrome","summary":"Corcept Therapeutics announced positive topline results from a Phase 3 clinical trial of Korlym in patients with Cushing's syndrome.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-04-05","type":"regulatory","source":"simplywall.st","summary":"Corcept Therapeutics (CORT) Is Up 13.0% After FDA Approves Lifyorli Combo in Resistant Ovarian Cancer - simplywall.st","headline":"Corcept Therapeutics (CORT) Is Up 13.0% After FDA Approves Lifyorli Combo in Resistant Ovarian Cancer","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9vOEJXMFBTS3c4aG1MdWJZc3htcmk1QnZZYUhXUE9ENnhMV3RiNEItWDlGUEQyVmphdU5PcWxOLXZramlla1BxQ1dKOS13ZUZqNWNXa2xEVkhiTUUwVHdR?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill","headline":"CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-27","type":"pipeline","source":"simplywall.st","summary":"Is Corcept Therapeutics (CORT) Pricing Reflect Its Recent Share Rebound And DCF Upside Potential - simplywall.st","headline":"Is Corcept Therapeutics (CORT) Pricing Reflect Its Recent Share Rebound And DCF Upside Potential","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxPU1gtYnBBNXJ3YW5iVXFwOHhDRUpablVjcmtsOEZhZVZSSF9nUFI2dnJtRWp6RGM0UjF2NUg4MkIyWFR4RlBkMmlsc0JOdUwxZE43RlNWZmxCbmoxUnlCWUcwOGVVYXFKQTZBYlpNTGo5bXdxdjRhNTRSYmpsMmYyZGVpdlQwLVJ6NThvWHZXa3NlUzB2aGM2YkdsYmRhUnhabVB5OHJLd3FfWW9ma1VGS0xoUUlGenB0UUR6ZkplVHJVVVdTTzJuaXRZOEQtMG9OdGNYM1c1aGlLZEU?oc=5","date":"2026-03-25","type":"regulatory","source":"reuters.com","summary":"Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer - reuters.com","headline":"Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer","sentiment":"neutral"},{"date":"2026-03-25","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxOTDh0ZlIyN0NmV2VZRV9hblMtMTVOZzVWajZySGQ0WVNXVURmdU1kR0FNNloyZ01QcnYyN0hoc21UcHY2QjBNUlpqald0dnZEV3dXRGk2bmxTWU9JZFZtajAtWUpwUXlLUjgzRFlzcU9vQmMtOHNqUG9sLVhxVzU4ZW45Rk1KZ2dVcGdmdlIzdWRtSF9sYzFsaFBlRjhSQnJGZkpHOHc3dUQ2TnBpamc?oc=5","date":"2026-03-23","type":"earnings","source":"Yahoo Finance","summary":"Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks - Yahoo Finance","headline":"Q4 Earnings Outperformers: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Stocks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxQOE1wZlRRVVEzSWZBcFprVTFEc1lLUFlyeTd1azRhNnlWdTlsQUZqT2M4RlRqOWRDcUNCQ2Q2T25sNVBBQk1WSmh4c0RFLVJvNVh3SDlzd2xLa1AwRmFQbFRqamhUZ0p3VTFTYmtYNUFjRVlVcnRGWW50TWR3NFRReGRjcDBCbXJMZTRmbENwUmYyZFY4MUJzY3NXMFVWYjhuaDB1a09mY21xX2VnMnI2RFUzYjVRTzBiM3c1YnZVc3JGZw?oc=5","date":"2026-02-19","type":"patent","source":"Business Wire","summary":"Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals - Business Wire","headline":"Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxPNE5Cbm1ja011QTZsWlE0elphTmZrcm9RdnZmNmFvNl94aFdPeUpsWExqb2t5YU5JbkJzRkRncHRXTU02Y0p1dnJ1Tlp2dmJ5SmoxZ1pub2hmQ3d0bE54R0w5TGF6Y1ROalNWQktkY3hPLWtBWGRmQm96S2dwT2xtWnJsOUdjazJZNW1Sb3FuYmdSMmE0dXBYcVFCM3NiUVU?oc=5","date":"2026-01-09","type":"regulatory","source":"Finviz","summary":"Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter - Finviz","headline":"Price Targets Lowered on Corcept Therapeutics (CORT) After FDA Letter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE55dURGdEFGZmZHV2JMM2V5ZDN1SmRCMEs3OE1PTk5DdnBkR0phQkJ2Nzk0bEYwYWcyeHRFV2V5WWdDZy1wd2NGeWk2X0xjOHdOUEcwd0NfN0RZaDBhNlk1SlFfOFdWZm5qdTJZa29abWswdGFyeDJDRQ?oc=5","date":"2026-01-05","type":"pipeline","source":"Yahoo Finance","summary":"Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? - Yahoo Finance","headline":"Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPQVgta1MtNzViV05DMGIzMjJ5bWxFTE5yZk11UlRFR2xuWm9rRVEyWWJoX3lZelhVejg0ZG0tQ0JFdm5JbkV4LUF2aVJmZHJtWWg0aTZKU0VUMi0xaE1qcmF2b3Zic1V0dktvaDk5SGxCRWNqYTJUYUxDZG44TTk5V1BlQVRaaEtoTEFqM1paWFdteklFTHhsQ3U4a0NNcGxUbmRva21OY1M4bVNma3BTU1NWbFhVYlhtd2hOQndvS2JOLUpxOUZIOTNGc0I?oc=5","date":"2026-01-02","type":"regulatory","source":"reuters.com","summary":"US FDA declines to approve Corcept's drug for rare hormonal disorder - reuters.com","headline":"US FDA declines to approve Corcept's drug for rare hormonal disorder","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQZkE4cjFVaG9NcmJJWHRRM0FmRkxtb1cwaVRTTlpiMFdDYjVqaHVRVk05Z3BJZ2xBZVVfNGVZMjYwWXNXUHJLdFloRVAyNlNSSXM0TWNHYjN6Qnc0bXNfTFIzWFd0ZXNISGRaSlpTZnlobW40c3BlbFRJVFJBeG1kUG80ZjE0RmR1TnJiRHdmcVk0bVRaYlRQUkhIZmV3eVo1a3JTdE9DSmdGQjdMbzQtODVldGF0ZEstOE9BMzMzS0EtZ0o0ZGIyQ3V0RHYxdlk0QTJkSnJXSQ?oc=5","date":"2025-12-31","type":"pipeline","source":"Trefis","summary":"Would You Still Hold Corcept Therapeutics Stock If It Fell Another 30%? - Trefis","headline":"Would You Still Hold Corcept Therapeutics Stock If It Fell Another 30%?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPLXYtQy1vSDdFb2JFVUZiVFBDSllKaFdFWDNnelY0ZkpuODlqTWZwcS1vVjFOWmV0M0xldml3OEF4ekF1bU9MS2p4bUxmakNrZGFYc0Q2NmNhNjBEWURuaHQ5eGs1cFF3SzU1aTRqWkhlV0w0OEQzT0ZkUVVsemNCb2cyWWMwZw?oc=5","date":"2025-12-31","type":"regulatory","source":"Seeking Alpha","summary":"Corcept down as FDA rejects hormonal therapy (CORT:NASDAQ) - Seeking Alpha","headline":"Corcept down as FDA rejects hormonal therapy (CORT:NASDAQ)","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQNWFMQU11MU5UTFRmNXd4b1k2dU82LVQ1aWFlejVDTkUzVzUxMGlRUEJmdms4alBzNW1IMWNaWkRjalNfSlVmUm9tMm0tTWlub2huNG5vdGZGbjFuZHJDQ0Vrbl9SYjdaeE1IRVJhMWJtZUlrZ05vMFFqT1Z4NUptNHB2bUszdw?oc=5","date":"2025-12-31","type":"pipeline","source":"TipRanks","summary":"Why Is Corcept Therapeutics Stock (CORT) Down Today? - TipRanks","headline":"Why Is Corcept Therapeutics Stock (CORT) Down Today?","sentiment":"neutral"}],"patents":[{"drugName":"Korlym","drugSlug":"mifepristone","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":123800000}],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_2":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Pfizer","Eli Lilly","Novartis"],"therapeuticFocus":["Endocrinology","Specialty Pharma"],"financials":{"source":"sec_edgar","revenue":761407000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":761407000,"period":"2025-12-31"},{"value":675040000,"period":"2024-12-31"},{"value":675040000,"period":"2024-12-31"},{"value":482375000,"period":"2023-12-31"},{"value":482375000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":254908000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":99652000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":836651000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":42.99,"previousClose":41.69,"fiftyTwoWeekHigh":91,"fiftyTwoWeekLow":28.66,"fiftyTwoWeekRange":"28.66 - 91.0","fiftyDayAverage":37.85,"twoHundredDayAverage":63.27,"beta":0.25,"enterpriseValue":4068687872,"forwardPE":26.7,"priceToBook":7.03,"priceToSales":6.01,"enterpriseToRevenue":5.34,"enterpriseToEbitda":88.55,"pegRatio":0,"ebitda":45946000,"ebitdaMargin":6,"freeCashflow":114190128,"operatingCashflow":141996000,"totalDebt":6107000,"debtToEquity":0.9,"currentRatio":2.92,"returnOnAssets":3.3,"returnOnEquity":15,"analystRating":"1.8 - Buy","recommendationKey":"buy","numberOfAnalysts":5,"targetMeanPrice":67.4,"targetHighPrice":110,"targetLowPrice":44,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":11.4,"institutionHeldPercent":72.9,"sharesOutstanding":106374020,"floatShares":87877705,"sharesShort":13027166,"shortRatio":7.1,"shortPercentOfFloat":12.2,"epsTrailing":0.82,"epsForward":1.61,"revenuePerShare":7.33,"bookValue":6.11,"officers":[{"age":68,"name":"Dr. Joseph K. Belanoff M.D.","title":"Co-Founder, President, CEO & Director"},{"age":48,"name":"Mr. Atabak  Mokari","title":"CFO & Treasurer"},{"age":48,"name":"Mr. Sean  Maduck","title":"President of Endocrinology"},{"age":57,"name":"Dr. William  Guyer Pharm.D.","title":"Chief Development Officer"},{"age":62,"name":"Mr. Gary Charles Robb J.D.","title":"Chief Business Officer & Secretary"},{"age":46,"name":"Mr. Joseph Douglas Lyon","title":"Chief Technology & Accounting Officer"},{"age":65,"name":"Dr. Hazel  Hunt Ph.D.","title":"Chief Scientific Officer"},{"age":null,"name":"Ms. Amy  Flood","title":"Chief Human Resources & Communications Officer"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.corcept.com","phone":"650 327 3270"}}